| Symbol | PHAT |
|---|---|
| Name | PHATHOM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 CAMPUS DRIVE,SUITE 102, FLORHAM PARK, New Jersey, 07932, United States |
| Telephone | +1 877 742-8466 |
| Fax | — |
| — | |
| Website | https://www.phathompharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001783183 |
| Description | Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. Additional info from NASDAQ: |
Parikh Asit 🟡 adjusted position in 0 shares of Phathom Pharmaceuticals, Inc. (PHAT) Transaction Date: May 22, 2026 | Filing ID: 241984
Read moreParikh Asit 🟡 adjusted position in 24.1K shares (1 derivative) of Phathom Pharmaceuticals, Inc. (PHAT) at $4.95 Transaction Date: May 19, 2026 | Filing ID: 234891
Read moreTopper James N 🟢 acquired 24.1K shares of Phathom Pharmaceuticals, Inc. (PHAT) Transaction Date: May 19, 2026 | Filing ID: 234572
Read moreStenhouse Mark 🟢 acquired 24.1K shares of Phathom Pharmaceuticals, Inc. (PHAT) Transaction Date: May 19, 2026 | Filing ID: 234568
Read moreFIELDS HEIDI 🟢 acquired 24.1K shares of Phathom Pharmaceuticals, Inc. (PHAT) Transaction Date: May 19, 2026 | Filing ID: 234567
Read moreCOLA MICHAEL F 🟢 acquired 24.1K shares of Phathom Pharmaceuticals, Inc. (PHAT) Transaction Date: May 19, 2026 | Filing ID: 234566
Read morePhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Read morePhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Read more(30% Negative) PHATHOM PHARMACEUTICALS, INC. (PHAT) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06851559 | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to… | Phase2 | Eosinophilic Esophagitis | Recruiting | 2025-10-30 | 2027-03-01 | ClinicalTrials.gov |
| NCT06851559 | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to… | Phase2 | Eosinophilic Esophagitis | Recruiting | 2025-10-30 | 2027-03-01 | ClinicalTrials.gov |
| NCT06660342 | A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspr… | — | Erosive Esophagitis | Recruiting | 2025-05-15 | 2034-09-01 | ClinicalTrials.gov |
| NCT06660342 | A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspr… | — | Erosive Esophagitis | Recruiting | 2025-05-15 | 2034-09-01 | ClinicalTrials.gov |
| NCT06831344 | A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Ad… | Phase1 | Healthy Volunteers | Completed | 2025-02-14 | 2025-04-10 | ClinicalTrials.gov |
| NCT06831344 | A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Ad… | Phase1 | Healthy Volunteers | Completed | 2025-02-14 | 2025-04-10 | ClinicalTrials.gov |
| NCT07224048 | Helicobacter Pylori Screening and Treatment in the At-risk South Florida Commun… | Phase4 | H. Pylori Infection | Active_Not_Recruiting | 2024-11-06 | 2027-11-06 | ClinicalTrials.gov |
| NCT07224048 | Helicobacter Pylori Screening and Treatment in the At-risk South Florida Commun… | Phase4 | H. Pylori Infection | Active_Not_Recruiting | 2024-11-06 | 2027-11-06 | ClinicalTrials.gov |
| NCT06391177 | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactati… | Phase1 | Erosive Esophagitis | Completed | 2024-05-07 | 2024-09-19 | ClinicalTrials.gov |
| NCT06391177 | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactati… | Phase1 | Erosive Esophagitis | Completed | 2024-05-07 | 2024-09-19 | ClinicalTrials.gov |
| NCT06106022 | A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophagea… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2023-11-01 | 2024-04-29 | ClinicalTrials.gov |
| NCT06106022 | A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophagea… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2023-11-01 | 2024-04-29 | ClinicalTrials.gov |
| NCT07224035 | Helicobacter Pylori Screening and Treatment in the At-risk South Florida Commun… | Phase4 | H Pylori Infection | Active_Not_Recruiting | 2022-10-15 | 2027-11-06 | ClinicalTrials.gov |
| NCT07224035 | Helicobacter Pylori Screening and Treatment in the At-risk South Florida Commun… | Phase4 | H Pylori Infection | Active_Not_Recruiting | 2022-10-15 | 2027-11-06 | ClinicalTrials.gov |
| NCT05366738 | A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pud… | Phase1 | Healthy Volunteers | Completed | 2022-05-18 | 2022-07-26 | ClinicalTrials.gov |
| NCT05366738 | A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pud… | Phase1 | Healthy Volunteers | Completed | 2022-05-18 | 2022-07-26 | ClinicalTrials.gov |
| NCT05343364 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonopr… | Phase1 | Gastroesophageal Reflux | Completed | 2022-05-09 | 2023-06-13 | ClinicalTrials.gov |
| NCT05343364 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonopr… | Phase1 | Gastroesophageal Reflux | Completed | 2022-05-09 | 2023-06-13 | ClinicalTrials.gov |
| NCT05195528 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo f… | Phase3 | Non-Erosive Gastro-Esophageal Reflux Disease | Completed | 2022-01-17 | 2023-05-17 | ClinicalTrials.gov |
| NCT05195528 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo f… | Phase3 | Non-Erosive Gastro-Esophageal Reflux Disease | Completed | 2022-01-17 | 2023-05-17 | ClinicalTrials.gov |
| NCT04799158 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo i… | Phase2 | Non-Erosive Gastro-Esophageal Reflux Disease | Completed | 2021-03-25 | 2022-01-17 | ClinicalTrials.gov |
| NCT04799158 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo i… | Phase2 | Non-Erosive Gastro-Esophageal Reflux Disease | Completed | 2021-03-25 | 2022-01-17 | ClinicalTrials.gov |
| NCT04729101 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonopra… | Phase1 | Healthy Participants | Completed | 2021-01-28 | 2021-06-26 | ClinicalTrials.gov |
| NCT04729101 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonopra… | Phase1 | Healthy Participants | Completed | 2021-01-28 | 2021-06-26 | ClinicalTrials.gov |
| NCT04558216 | Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healt… | Phase1 | Healthy Participants | Withdrawn | 2020-09-30 | 2021-02-19 | ClinicalTrials.gov |
| NCT04558216 | Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healt… | Phase1 | Healthy Participants | Withdrawn | 2020-09-30 | 2021-02-19 | ClinicalTrials.gov |
| NCT04545944 | Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Par… | Phase1 | Healthy Volunteers | Completed | 2020-09-15 | 2020-11-25 | ClinicalTrials.gov |
| NCT04545944 | Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Par… | Phase1 | Healthy Volunteers | Completed | 2020-09-15 | 2020-11-25 | ClinicalTrials.gov |
| NCT04167670 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With… | Phase3 | Helicobacter Pylori Infection | Completed | 2019-12-10 | 2021-03-18 | ClinicalTrials.gov |
| NCT04167670 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With… | Phase3 | Helicobacter Pylori Infection | Completed | 2019-12-10 | 2021-03-18 | ClinicalTrials.gov |
| NCT04124926 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With… | Phase3 | Erosive Esophagitis | Completed | 2019-10-28 | 2021-08-24 | ClinicalTrials.gov |
| NCT04124926 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With… | Phase3 | Erosive Esophagitis | Completed | 2019-10-28 | 2021-08-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Non-Erosive Gastro-Esophageal Reflux Disease | COMPLETED | NCT05195528 |
| Vonoprazan | Other | Phase PHASE3 | Non-Erosive Gastro-Esophageal Reflux Disease | COMPLETED | NCT05195528 |
| Rifampin | Other | Phase PHASE1 | Healthy Participants | WITHDRAWN | NCT04558216 |
| Vonoprazan | Other | Phase PHASE1 | Healthy Participants | WITHDRAWN | NCT04558216 |
| Lansoprazole | Other | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT04167670 |
| Clarithromycin | Other | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT04167670 |
| Amoxicillin | Other | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT04167670 |
| Vonoprazan | Other | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT04167670 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT04124926 |
| Vonoprazan | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT04124926 |
| Placebo | Other | Phase PHASE2 | Non-Erosive Gastro-Esophageal Reflux Disease | COMPLETED | NCT04799158 |
| Vonoprazan | Other | Phase PHASE2 | Non-Erosive Gastro-Esophageal Reflux Disease | COMPLETED | NCT04799158 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04545944 |
| Vonoprazan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04545944 |
| Lansoprazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04729101 |
| Vonoprazan | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04729101 |
| Vonoprazan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05366738 |
| Vonoprazan | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT06106022 |
| Vonoprazan | Other | Phase PHASE1 | Erosive Esophagitis | COMPLETED | NCT06391177 |
| Vonoprazan | Other | Phase PHASE1 | Gastroesophageal Reflux | COMPLETED | NCT05343364 |
| Vonoprazan | Other | Preclinical | Erosive Esophagitis | RECRUITING | NCT06660342 |
| Vonoprazan (Reference) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06831344 |
| Vonoprazan ODT-1 or ODT-2 with Water | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06831344 |
| Vonoprazan ODT-1 or ODT-2 without Water | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06831344 |
| PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person) | Other | Phase PHASE4 | H. Pylori Infection | ACTIVE_NOT_RECRUITING | NCT07224048 |
| PYTEST® 14C-Urea Capsule Breath Test (at Home) | Other | Phase PHASE4 | H. Pylori Infection | ACTIVE_NOT_RECRUITING | NCT07224048 |
| VOQUEZNA® Triple Pak® | Other | Phase PHASE4 | H Pylori Infection | ACTIVE_NOT_RECRUITING | NCT07224035 |
| PYTEST® 14C-Urea Breath Test | Other | Phase PHASE4 | H Pylori Infection | ACTIVE_NOT_RECRUITING | NCT07224035 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Vonoprazan | Other | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Low dose IL-2 | BIOLOGICAL | Phase PHASE1 | HNSCC | ACTIVE_NOT_RECRUITING | NCT05902520 |
| DP CD8 TIL KD | BIOLOGICAL | Phase PHASE1 | HNSCC | ACTIVE_NOT_RECRUITING | NCT05902520 |
| DP CD8 TIL | BIOLOGICAL | Phase PHASE1 | HNSCC | ACTIVE_NOT_RECRUITING | NCT05902520 |
| PH-762 | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of the Skin | ACTIVE_NOT_RECRUITING | NCT06014086 |
| Vonoprazan (Reference) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06831344 |
| Vonoprazan ODT-1 or ODT-2 with Water | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06831344 |
| Vonoprazan ODT-1 or ODT-2 without Water | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06831344 |
| Placebo | DRUG | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |
| Rifampin | DRUG | Phase PHASE1 | Healthy Participants | WITHDRAWN | NCT04558216 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04545944 |
| Clarithromycin | DRUG | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT04167670 |
| Amoxicillin | DRUG | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT04167670 |
| Lansoprazole | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04729101 |
| Vonoprazan | DRUG | Phase PHASE2 | Eosinophilic Esophagitis | RECRUITING | NCT06851559 |